Aprea Financial Statements From 2010 to 2026

APRE Stock  USD 0.90  0.02  2.17%   
Aprea Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Aprea Therapeutics' valuation are provided below:
Gross Profit
-7.9 M
Market Capitalization
6.3 M
Revenue
488.2 K
Earnings Share
(2.12)
Quarterly Revenue Growth
(0.99)
There are over one hundred nineteen available fundamental signals for Aprea Therapeutics, which can be analyzed over time and compared to other ratios. Investors should ensure to validate all of Aprea Therapeutics' prevailing performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. As of January 15, 2026, Market Cap is expected to decline to about 19.8 M. The current year's Enterprise Value is expected to grow to about (5.2 M)

Aprea Therapeutics Total Revenue

1.81 Million

Check Aprea Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aprea Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 541.8 K, Selling General Administrative of 8.1 M or Total Revenue of 1.8 M, as well as many indicators such as Price To Sales Ratio of 22.67, Dividend Yield of 0.0 or PTB Ratio of 0.89. Aprea financial statements analysis is a perfect complement when working with Aprea Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Aprea Stock
Check out the analysis of Aprea Therapeutics Correlation against competitors.
For information on how to trade Aprea Stock refer to our How to Trade Aprea Stock guide.

Aprea Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets40.1 M21.6 M38.9 M
Pretty Stable
Other Current Liabilities4.3 M2.3 M3.4 M
Slightly volatile
Total Current Liabilities6.4 M3.9 M5.5 M
Pretty Stable
Accounts Payable1.8 M1.2 M2.1 M
Slightly volatile
Cash38.7 M20.6 M37.7 M
Pretty Stable
Other Assets32.1 K33.8 K33.7 K
Pretty Stable
Net Receivables6.7 K7.5 K8.2 K
Slightly volatile
Total LiabilitiesM4.2 M25.4 M
Pretty Stable
Total Current Assets39.9 M21.2 M38.7 M
Pretty Stable
Common Stock4.7 K4.9 K54.6 K
Slightly volatile
Property Plant EquipmentK2.1 K96.8 K
Very volatile
Property Plant And Equipment Net135.9 K73.4 K104.7 K
Slightly volatile
Non Current Assets Total244.8 K463.9 K159 K
Slightly volatile
Non Currrent Assets Other340.1 K323.9 K63.9 K
Slightly volatile
Cash And Short Term Investments19.5 M20.6 M38 M
Pretty Stable
Common Stock Total Equity18.1 K19.1 K76.8 K
Slightly volatile
Common Stock Shares Outstanding6.7 M6.3 M1.9 M
Slightly volatile
Liabilities And Stockholders Equity20.5 M21.6 M39.2 M
Pretty Stable
Non Current Liabilities Total1.1 M1.2 M33.6 M
Slightly volatile
Capital Surpluse136.6 M266.1 M115.3 M
Slightly volatile
Other Current Assets793.4 K835.2 KM
Slightly volatile
Other Stockholder Equity241.2 M403.6 M149.1 M
Slightly volatile
Property Plant And Equipment Gross151.1 K138.6 K118.4 K
Slightly volatile
Net Working Capital17.3 M18.2 M33.9 M
Pretty Stable
Capital Stock4.7 K4.9 K72.3 K
Slightly volatile
Short and Long Term Debt Total285.5 K171.4 K412 K
Slightly volatile
Current Deferred Revenue423.2 K476.1 K519.6 K
Slightly volatile

Aprea Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative8.1 M7.4 M6.1 M
Slightly volatile
Interest Income865.4 K1.5 M781 K
Slightly volatile
Depreciation And Amortization19.1 K20.1 K48 K
Pretty Stable
Other Operating Expenses17.3 M18.2 M26.1 M
Slightly volatile
Research Development10.2 M10.8 M19.7 M
Pretty Stable

Aprea Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock111.8 M106.5 M58.4 M
Slightly volatile
Depreciation19.1 K20.1 K68 K
Pretty Stable
Total Cash From Financing Activities17.5 M13.3 M21.6 M
Pretty Stable
End Period Cash Flow39.9 M20.6 M36.7 M
Slightly volatile
Stock Based Compensation534.7 K562.9 K2.2 M
Slightly volatile
Begin Period Cash Flow18.5 M19.5 M32.9 M
Slightly volatile
Issuance Of Capital Stock13.8 M14.5 M43.5 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio22.6713.8726.8672
Slightly volatile
Average Payables2.5 M1.7 MM
Very volatile
Stock Based Compensation To Revenue0.590.370.7032
Slightly volatile
Capex To Depreciation0.590.622.6945
Slightly volatile
Payables Turnover6.546.232.3228
Slightly volatile
Sales General And Administrative To Revenue4.74.9412.7199
Slightly volatile
Research And Ddevelopement To Revenue10.627.1712.1831
Slightly volatile
Capex To Revenue0.01130.01180.1334
Slightly volatile
Cash Per Share4.534.7758.89
Pretty Stable
Days Payables Outstanding57.5960.6246.4 K
Slightly volatile
Income Quality0.941.20.9039
Very volatile
Net Debt To EBITDA2.41.841.9386
Very volatile
Current Ratio9.548.077.4813
Slightly volatile
Debt To Equity0.00460.00440.0043
Slightly volatile
Capex Per Share0.00310.00320.0111
Slightly volatile
Revenue Per Share0.180.250.1741
Slightly volatile
Interest Debt Per Share5.124.871.6259
Slightly volatile
Debt To Assets0.0040.00390.0039
Slightly volatile
Days Of Payables Outstanding57.5960.6246.4 K
Slightly volatile
Ebt Per Ebit1.061.040.9696
Slightly volatile
Total Debt To Capitalization0.00460.00440.0043
Slightly volatile
Debt Equity Ratio0.00460.00440.0043
Slightly volatile
Quick Ratio9.548.077.4813
Slightly volatile
Net Income Per E B T1.11.131.0151
Slightly volatile
Cash Ratio9.257.827.299
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.80.90.984
Slightly volatile
Fixed Asset Turnover10.0216.598.0852
Slightly volatile
Debt Ratio0.0040.00390.0039
Slightly volatile
Price Sales Ratio22.6713.8726.8672
Slightly volatile
Asset Turnover0.03540.05640.0303
Slightly volatile

Aprea Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap19.8 M20.8 M556.7 M
Slightly volatile

Aprea Fundamental Market Drivers

Aprea Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Aprea Therapeutics Financial Statements

Aprea Therapeutics stakeholders use historical fundamental indicators, such as Aprea Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Aprea Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Aprea Therapeutics' assets and liabilities are reflected in the revenues and expenses on Aprea Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Aprea Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue476.1 K423.2 K
Total Revenue1.7 M1.8 M
Cost Of Revenue10.8 M11.3 M
Stock Based Compensation To Revenue 0.37  0.59 
Sales General And Administrative To Revenue 4.94  4.70 
Research And Ddevelopement To Revenue 7.17  10.62 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.25  0.18 
Ebit Per Revenue(8.58)(9.01)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Aprea Therapeutics is a strong investment it is important to analyze Aprea Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aprea Therapeutics' future performance. For an informed investment choice regarding Aprea Stock, refer to the following important reports:
Check out the analysis of Aprea Therapeutics Correlation against competitors.
For information on how to trade Aprea Stock refer to our How to Trade Aprea Stock guide.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aprea Therapeutics. If investors know Aprea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aprea Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.12)
Revenue Per Share
0.08
Quarterly Revenue Growth
(0.99)
Return On Assets
(0.42)
Return On Equity
(0.75)
The market value of Aprea Therapeutics is measured differently than its book value, which is the value of Aprea that is recorded on the company's balance sheet. Investors also form their own opinion of Aprea Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aprea Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aprea Therapeutics' market value can be influenced by many factors that don't directly affect Aprea Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aprea Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aprea Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aprea Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.